Exagen Statistics
Want to see XGN full AI Analyst Report?
Exagen (XGN) Stock Statistics & Valuation Metrics
Total Valuation
Exagen has a market cap or net worth of $112.51M. The enterprise value is $202.70M.
- Market Cap
- $112.51M
- Enterprise Value
- $202.70M
Share Statistics
Exagen has 25,513,496 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 25,513,496
- Owned by Insiders
- 15.16%
- Owned by Institutions
- 21.74%
Financial Efficiency
Exagen’s return on equity (ROE) is -1.14 and return on invested capital (ROIC) is -30.02%.
- Return on Equity (ROE)
- -1.14
- Return on Assets (ROA)
- -0.34
- Return on Invested Capital (ROIC)
- -30.02%
- Return on Capital Employed (ROCE)
- -0.32
- Revenue Per Employee
- 308.22K
- Profits Per Employee
- -92.37K
- Employee Count
- 216
- Asset Turnover
- 1.15
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Exagen is -5.43. Exagen’s PEG ratio is -0.28.
- PE Ratio
- -5.43
- PS Ratio
- 1.46
- PB Ratio
- 7.45
- Price to FCF
- -8.09
- Price to Operating Cash Flow
- -8.54
- PEG Ratio
- -0.28
Income Statement
In the last 12 months, Exagen had revenue of 66.58M and earned -19.95M in profits. Earnings per share was -0.93.
- Revenue
- 66.58M
- Gross Profit
- 38.80M
- Operating Income
- -14.07M
- Pretax Income
- -19.90M
- Net Income
- -19.95M
- EBITDA
- -13.46M
- Earnings Per Share (EPS)
- -0.93
Cash Flow
In the last 12 months, operating cash flow was -12.02M and capital expenditures -1.01M, giving a free cash flow of -13.03M billion.
- Operating Cash Flow
- -12.02M
- Free Cash Flow
- -13.03M
- Free Cash Flow per Share
- -0.52
Dividends & Yields
Exagen pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -12.36%
- Earnings Yield
- -17.71%
Stock Price Statistics
- Beta
- 1.69
- 52-Week Price Change
- -55.83%
- 50-Day Moving Average
- 7.84
- 200-Day Moving Average
- 5.13
- Relative Strength Index (RSI)
- 28.75
- Average Volume (3m)
- 441.99K
Important Dates
Exagen upcoming earnings date is Mar 16, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Mar 16, 2027
- Ex-Dividend Date
- ―
Financial Position
Exagen as a current ratio of 3.45, with Debt / Equity ratio of 147.32%
- Current Ratio
- 3.45
- Quick Ratio
- 3.45
- Debt to Market Cap
- 0.17
- Net Debt to EBITDA
- 0.48
- Interest Coverage Ratio
- -3.26
Taxes
In the past 12 months, Exagen has paid 51.00K in taxes.
- Income Tax
- 51.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Exagen EV to EBITDA ratio is -9.39, with an EV/FCF ratio of -8.14.
- EV to Sales
- 1.47
- EV to EBITDA
- -9.39
- EV to Free Cash Flow
- -8.14
- EV to Operating Cash Flow
- -8.82
Balance Sheet
Exagen has $28.09M in cash and marketable securities with $28.76M in debt, giving a net cash position of -$669.00K billion.
- Cash & Marketable Securities
- $28.09M
- Total Debt
- $28.76M
- Net Cash
- -$669.00K
- Net Cash Per Share
- -$0.03
- Tangible Book Value Per Share
- $0.55
Margins
Gross margin is 58.74%, with operating margin of -20.08%, and net profit margin of -25.14%.
- Gross Margin
- 58.74%
- Operating Margin
- -20.08%
- Pretax Margin
- -25.07%
- Net Profit Margin
- -25.14%
- EBITDA Margin
- -15.63%
- EBIT Margin
- -18.15%
Analyst Forecast
The average price target for Exagen is $10.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $10.00
- Price Target Upside
- 142.13% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- 13.67%
- EPS Growth Forecast
- 18.80%
Scores
- Smart Score
- 7
- AI Score
- 45
